Why liver disease newco Alentis is aiming for one of largest Swiss A rounds

BioMedPartners, BB Pureos Bioventures lead $12M first close for Basel start-up

By Stephen Hansen, Associate Editor | Apr 30, 2019 | 12:01 AM GMT

Liver disease newco Alentis Therapeutics is starting off small with the first close of its series A round, but the additional capital it expects to raise over the next six months could give it the largest series A for a Swiss biotech since 2015.

Founded in

Read the full 453 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE